BioMarin Shares Jump 5% After Global Patent Settlement With Ascendis
BioMarin Pharmaceutical Inc.
Ascendis Pharma A/S (ASND)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Dorset Management David M. Knott | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $246.91 | 900 | $222,219.00 | 2,900 | 2026-08-14 | Filing | |
| $245.85 | 1,100 | $270,435.00 | 2,000 | 2026-08-14 | Filing | |
| $219.00 | 100 | $21,900.00 | 4,367 | 2026-06-02 | Filing | |
| $223.50 | 100 | $22,350.00 | 900 | 2026-05-29 | Filing | |
| $222.30 | 200 | $44,460.00 | 800 | 2026-05-29 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $270.19 | 3,000 | $810,570.00 | 0 | 2026-09-08 | Filing | |
| $264.13 | 236 | $62,334.59 | 4,000 | 2026-09-02 | Filing | |
| $238.49 | 19,460 | $4,641,021.24 | 0 | 2026-05-11 | Filing |
News See All
Ascendis Pharma Stock (ASND) Soars 7% on a Settlement with BioMarin Pharmaceutical (BMRN)
Ascendis Pharma stock rallied 7% on Monday after the company reached a global settlement and license deal with BioMarin Pharmaceutical.
Ascendis Pharma (ASND): Three New Drugs Are Turning This Biotech Into A Growth Machine
On August 13, Ascendis Pharma (NASDAQ:ASND) reported second-quarter results that showed how far its rare disease portfolio has come.
Artisan Small Cap Fund Trimmed Ascendis Pharma (ASND) Amid Lawsuit Concerns
Artisan Partners, an investment management company, released its second-quarter 2026 investor letter for its "Artisan Small Cap Fund". A copy of the letter can be downloaded here.
10 Most Profitable Growth Stocks to Buy
In this article, we will discuss the 10 Most Profitable Growth Stocks to Buy.
Ascendis Pharma A/S (NASDAQ:ASND) Q1 2026 Earnings Call Transcript
Ascendis Pharma A/S (NASDAQ:ASND) Q1 2026 Earnings Call Transcript May 7, 2026Ascendis Pharma A/S beats earnings expectations. Reported EPS is $0.32, expectations were $0.21.
Billionaire Joe Edelman's 10 Stock Picks with Huge Upside Potential
In this article, we discuss the Billionaire Joe Edelman's Stock Picks with Huge Upside Potential.
7 Best Strong Buy European Stocks to Invest In
In this article, we will look at the 7 Best Strong Buy European Stocks to Invest In. European stocks are getting a closer look as investors search beyond the crowded parts of the U.S.
7 Fastest Growing European Stocks to Invest In
In this article, we will look at the 7 Fastest Growing European Stocks to Invest In.
Ascendis Pharma (ASND) Revenue Nearly Doubles to €720M in 2025 Fueled by Core Product Growth
Ascendis Pharma (NASDAQ:ASND) is one of the best NASDAQ growth stocks to buy for the next 2 years.
Hedge Fund Resource Center